{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T04:03:41Z","timestamp":1769573021850,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11596-018-1976-0","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T00:59:24Z","timestamp":1544144364000},"page":"1005-1011","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients with Chronic Myeloid Leukemia: a Multicenter Retrospective Study in Hubei Province, China"],"prefix":"10.1007","volume":"38","author":[{"given":"Li-feng","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-lin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao-dong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deng-ju","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-bo","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,7]]},"reference":[{"key":"1976_CR1","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","volume":"114","author":"M Deininger","year":"2009","unstructured":"Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood, 2009,114:1126","journal-title":"Blood"},{"issue":"9","key":"1976_CR2","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","volume":"119","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, O'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood, 2012,119(9):1981\u20131987","journal-title":"Blood"},{"issue":"5","key":"1976_CR3","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood, 2012,119(5):1123\u20131129","journal-title":"Blood"},{"key":"1976_CR4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood.V124.21.152.152","volume":"124","author":"JE Cortes","year":"2014","unstructured":"Cortes JE, Saglio G, Baccarani M, et al. Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). Blood, 2014,124:152","journal-title":"Blood"},{"issue":"1","key":"1976_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bjh.13108","volume":"168","author":"TH Brummendorf","year":"2015","unstructured":"Brummendorf TH, Cortes JE, De Souza, et al. Bosutinib versus imatinib in newly diagnosed chronicphase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol, 2015,168(1):69\u201381","journal-title":"Br J Haematol"},{"issue":"18","key":"1976_CR6","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","volume":"125","author":"J Wang","year":"2015","unstructured":"Wang J, Shen ZX, Saglio G, et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood, 2015,125(18):2771\u20132778","journal-title":"Blood"},{"issue":"11","key":"1976_CR7","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","volume":"21","author":"EA Hahn","year":"2003","unstructured":"Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol, 2003,21(11):2138\u20132146","journal-title":"J Clin Oncol"},{"issue":"22","key":"1976_CR8","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood, 2009,113(22):5401\u20135411","journal-title":"Blood"},{"issue":"14","key":"1976_CR9","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","volume":"117","author":"AR Ibrahim","year":"2011","unstructured":"Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood, 2011,117(14):3733\u20133736","journal-title":"Blood"},{"issue":"22","key":"1976_CR10","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","volume":"121","author":"C Abboud","year":"2013","unstructured":"Abboud C, Berman E, Cohen A, et al. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood, 2013,121(22):4439\u20134442","journal-title":"Blood"},{"issue":"4","key":"1976_CR11","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","volume":"32","author":"SB Dusetzina","year":"2013","unstructured":"Dusetzina SB, Winn AN, Abel GA, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol, 2013,32(4):306\u2013311","journal-title":"J Clin Oncol"},{"issue":"1","key":"1976_CR12","doi-asserted-by":"publisher","first-page":"e004266","DOI":"10.1136\/bmjopen-2013-004266","volume":"4","author":"AG Smith","year":"2014","unstructured":"Smith AG, Painter D, Howell DA, et al. Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ Open, 2014,4(1):e004266","journal-title":"BMJ Open"},{"issue":"8","key":"1976_CR13","first-page":"651","volume":"36","author":"Q Jiang","year":"2015","unstructured":"Jiang Q, Zhao D, Jin J, et al. A prospective, multicentre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia. Zhonghua Xue Ye Xue Za Zhi (Chinese), 2015,36(8):651\u2013655","journal-title":"Zhonghua Xue Ye Xue Za Zhi (Chinese)"},{"issue":"9","key":"1976_CR14","first-page":"757","volume":"29","author":"CF Jiang","year":"2016","unstructured":"Jiang CF, Luo F, Lin SS, et al. Treatment of domestic imatinib Mesylate on 36 patients with Ph positivechronic myeloid leukemia. J Clin Hematol (China), 2016,29(9):757\u2013759","journal-title":"J Clin Hematol (China)"},{"issue":"3","key":"1976_CR15","first-page":"222","volume":"29","author":"JL Lv","year":"2016","unstructured":"Lv JL, Chen YP, Xiao Q, et al. Curative effect and safety analysis of 47 patients with chronic myeloid leukemia after imatinib Mesylate treatment. J Clin Hematol (China), 2016,29(3):222\u2013225","journal-title":"J Clin Hematol (China)"},{"issue":"11","key":"1976_CR16","first-page":"898","volume":"29","author":"J Kong","year":"2016","unstructured":"Kong J, Fu HX, Lai YH, et al. Dasatinib of china Tai-tianqing as second line treatment for chronic myelogenous leukemia in chronic phase. J Clin Hematol (Chinese), 2016,29(11):898\u2013901","journal-title":"J Clin Hematol (Chinese)"},{"issue":"6","key":"1976_CR17","first-page":"511","volume":"32","author":"H Min","year":"2016","unstructured":"Min H, Kaifeng Y, Xiaoming L, et al. Clinical effect of imatinib, nero imatinib and dasatinib on chronic myeloid leukemia in chronic phase. Chin J Clin Pharmacol, 2016,32(6):511\u2013513","journal-title":"Chin J Clin Pharmacol"},{"issue":"8","key":"1976_CR18","first-page":"633","volume":"37","author":"JX Wang","year":"2016","unstructured":"Wang JX. The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2016 edition). Zhonghua Xue Ye Xue Za Zhi (Chinese), 2016,37(8):633\u2013639","journal-title":"Zhonghua Xue Ye Xue Za Zhi (Chinese)"},{"issue":"1","key":"1976_CR19","first-page":"69","volume":"29","author":"PF Tan","year":"2016","unstructured":"Tan PF, Tan H, Luo XD. A case of chronic myeloid leukemia treated with dasatinib. J Clin Hematol (Chinese), 2016,29(1):69\u201370","journal-title":"J Clin Hematol (Chinese)"},{"key":"1976_CR20","first-page":"51","volume":"3","author":"R Ferdinand","year":"2012","unstructured":"Ferdinand R, Mitchell SA, Batson S, et al. Treatments for chronic myeloid leukemia: a qualitative systematic review. J Blood Med, 2012,3:51\u201376","journal-title":"J Blood Med"},{"issue":"19","key":"1976_CR21","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinibresistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol, 2008,26(19):3204\u20133212","journal-title":"J Clin Oncol"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-018-1976-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11596-018-1976-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-018-1976-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T19:29:31Z","timestamp":1575660571000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11596-018-1976-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1976"],"URL":"https:\/\/doi.org\/10.1007\/s11596-018-1976-0","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"7 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}